Third Harmonic Bio Executive Sells Shares Worth Over $71,000
Third Harmonic Bio Executive Sells Over $140k in Stock
Third Harmonic Bio (NASDAQ:THRD) Is In A Strong Position To Grow Its Business
Third Harmonic Bio to Participate in Upcoming Investor Conferences
Third Harmonic Shares Are Trading Higher on Continued Strength After the Company Reported Q2 Financial Results Yesterday. Also, Morgan Stanley Upgraded the Stock From Equal-Weight to Overweight and Raised Its Price Target From $12 to $20.
Express News | Third Harmonic Bio Inc : Morgan Stanley Raises to Overweight
Express News | Third Harmonic Bio Inc : Morgan Stanley Raises Target Price to $20.00 From $12.00
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20
Buy Rating Justified by Third Harmonic Bio's Promising Drug THB335 and Swift Clinical Advancements
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio GAAP EPS of $0.46
Third Harmonic Bio 2Q Net $18.6M >THRD
Express News | Third Harmonic Bio Q2 Net Income USD -10.7 Million
Express News | Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
Third Harmonic Bio | 10-Q: Q2 2024 Earnings Report
We're Interested To See How Third Harmonic Bio (NASDAQ:THRD) Uses Its Cash Hoard To Grow
Third Harmonic Bio(THRD.US) Officer Sells US$124.57K in Common Stock
$Third Harmonic Bio(THRD.US)$ Officer Person Julie sold 10,000 shares of common stock on Jun 26, 2024 at an average price of $12.4569 for a total value of $124.57K.Source: Announcement What is stateme
Form 144 | Third Harmonic Bio(THRD.US) Officer Proposes to Sell 125.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 26, $Third Harmonic Bio(THRD.US)$ Officer JULIE PERSON intends to sell 10,000 shares of its common stock on Jun 26, with a total market value of approximately $125.4K. JU
Stifel Starts Third Harmonic at Buy, Cites Mast Cell Disease Approach